<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Endocrinology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32153512</article-id>
<article-id pub-id-type="pmc">7047210</article-id>
<article-id pub-id-type="doi">10.3389/fendo.2020.00081</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Rare Variants in Genes Linked to Appetite Control and Hypothalamic Development in Early-Onset Severe Obesity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Loid</surname>
<given-names>Petra</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/849465/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mustila</surname>
<given-names>Taina</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mäkitie</surname>
<given-names>Riikka E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/574449/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Viljakainen</surname>
<given-names>Heli</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kämpe</surname>
<given-names>Anders</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/651965/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tossavainen</surname>
<given-names>Päivi</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipsanen-Nyman</surname>
<given-names>Marita</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pekkinen</surname>
<given-names>Minna</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mäkitie</surname>
<given-names>Outi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/535471/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Children's Hospital, Helsinki University Hospital</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff>
<aff id="aff2"><sup>2</sup><institution>Folkhälsan Research Center, Genetics Research Program</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff>
<aff id="aff3"><sup>3</sup><institution>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Pediatrics, Seinäjoki Central Hospital</institution>, <addr-line>Seinäjoki</addr-line>, <country>Finland</country></aff>
<aff id="aff5"><sup>5</sup><institution>City of Turku, Welfare Division, Preventive Healthcare</institution>, <addr-line>Turku</addr-line>, <country>Finland</country></aff>
<aff id="aff6"><sup>6</sup><institution>Molecular Endocrinology Laboratory, Department of Medicine, Hammersmith Campus, Imperial College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff7"><sup>7</sup><institution>The Department of Food and Nutrition, University of Helsinki</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff>
<aff id="aff8"><sup>8</sup><institution>Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Clinical Genetics, Karolinska University Hospital</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff>
<aff id="aff9"><sup>9</sup><institution>Department of Children and Adolescents, PEDEGO Research Unit, University of Oulu</institution>, <addr-line>Oulu</addr-line>, <country>Finland</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Paolo Marzullo, Università degli Studi del Piemonte Orientale, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Vibha Singhal, Massachusetts General Hospital and Harvard Medical School, United States; Beatrice Dubern, Hôpital Armand Trousseau, France</p>
</fn>
<corresp id="c001">*Correspondence: Petra Loid <email>petra.loid@helsinki.fi</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>81</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Loid, Mustila, Mäkitie, Viljakainen, Kämpe, Tossavainen, Lipsanen-Nyman, Pekkinen and Mäkitie.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Loid, Mustila, Mäkitie, Viljakainen, Kämpe, Tossavainen, Lipsanen-Nyman, Pekkinen and Mäkitie</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p><bold>Context:</bold> The hypothalamic circuit has an essential role in the regulation of appetite and energy expenditure. Pathogenic variants in genes involved in the hypothalamic leptin–melanocortin pathway, including melanocortin-4-receptor (<italic>MC4R</italic>), have been associated with monogenic obesity.</p>
<p><bold>Objective:</bold> To determine the rate and spectrum of rare variants in genes involved in melanocortin pathway or hypothalamic development in patients with severe early-onset obesity (height-adjusted weight &gt;60% before age 10 years).</p>
<p><bold>Methods:</bold> We used a custom-made targeted exome sequencing panel to assess peripheral blood DNA samples for rare (minor allele frequency &lt;0.5%), pathogenic/likely pathogenic variants in 24 genes related to the hypothalamic circuit in 92 subjects (51% males, median age 13.7 years) with early-onset severe obesity (median body mass index (BMI) Z-score + 4.0).</p>
<p><bold>Results:</bold> We identified a novel frameshift deletion in <italic>MC4R</italic> (p.V103Afs5<sup>*</sup>) in two unrelated patients and a previously reported <italic>MC4R</italic> variant (p.T112M) in one patient. In addition, we identified rare heterozygous missense variants in <italic>ADCY3</italic> (p.G1110R), <italic>MYT1L</italic> (p.R807Q), <italic>ISL1</italic> (p.I347F), <italic>LRP2</italic> (p.R2479I, and p.N3315S) and a hemizygous missense variant in <italic>GRPR</italic> (p.L87M) (each in one patient), possibly contributing to the obesity phenotype in these patients. Altogether 8 % (7/92) of the subjects had rare pathogenic/likely pathogenic variants in the studied genes.</p>
<p><bold>Conclusions:</bold> Rare genetic variants within the hypothalamic circuit are prevalent and contribute to the development of severe early-onset obesity. Targeted exome sequencing is useful in identifying affected subjects. Further studies are needed to evaluate the variants' clinical significance and to define optimal treatment.</p>
</abstract>
<kwd-group>
<kwd>childhood obesity</kwd>
<kwd>hypothalamus</kwd>
<kwd>appetite regulation</kwd>
<kwd>hyperphagia</kwd>
<kwd>
<italic>MC4R</italic>
</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Academy of Finland<named-content content-type="fundref-id">10.13039/501100002341</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">Sigrid Juséliuksen Säätiö<named-content content-type="fundref-id">10.13039/501100006306</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn003">Lastentautien Tutkimussäätiö<named-content content-type="fundref-id">10.13039/501100005744</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn004">Samfundet Folkhälsan<named-content content-type="fundref-id">10.13039/501100004810</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn005">Päivikki ja Sakari Sohlbergin Säätiö<named-content content-type="fundref-id">10.13039/501100004212</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn006">Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne<named-content content-type="fundref-id">10.13039/100010119</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn007">Emil Aaltosen Säätiö<named-content content-type="fundref-id">10.13039/501100004756</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn008">Vetenskapsrådet<named-content content-type="fundref-id">10.13039/501100004359</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn009">Novo Nordisk Fonden<named-content content-type="fundref-id">10.13039/501100009708</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn010">Helsingin Yliopisto<named-content content-type="fundref-id">10.13039/100007797</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn011">Helsingin ja Uudenmaan Sairaanhoitopiiri<named-content content-type="fundref-id">10.13039/100008376</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="43"></ref-count>
<page-count count="9"></page-count>
<word-count count="6668"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Obesity is a complex disease with various contributing environmental and genetic factors. To uncover the principal genetic factors behind obesity, several advanced research strategies have been used, including twin studies, genome-wide association studies (GWASs), chromosomal microarray analyses and next generation sequencing (<xref ref-type="bibr" rid="B1">1</xref>). For example, common single nucleotide polymorphisms (SNPs) in multiple genes have been shown to modulate the risk of obesity, although each of these have only a minor effect on body mass index (BMI) variation (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). We and others have also shown that rare copy number variants (CNVs) are enriched in patients with early-onset severe obesity (<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>). Recently, it has also been suggested that obesity could be a consequence of rare genetic variants with strong effect (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Despite these advancements, the genetic causes and underlying molecular mechanisms behind obesity are still inadequately understood.</p>
<p>Mutations in genes linked to the leptin-melanocortin signaling in the hypothalamus are associated with monogenic obesity. These genes include i.e., <italic>LEP, LEPR, POMC, PCSK1, MC4R, MC3R, SH2B1, NTRK2, MRAP2</italic>, and <italic>TUB</italic> (<xref ref-type="bibr" rid="B1">1</xref>). The discovery of these monogenic mutations has increased our understanding of the mechanisms controlling energy balance. Single-gene mutations are estimated to account for ~7% of cases of non-syndromic severe obesity (<xref ref-type="bibr" rid="B1">1</xref>). Of them, <italic>MC4R</italic> mutations are the most frequent with over 300 reported variants (<xref ref-type="bibr" rid="B9">9</xref>). The prevalence of pathogenic variants in <italic>MC4R</italic> in Finnish patients with early-onset obesity was reported to be 1.8% (<xref ref-type="bibr" rid="B10">10</xref>), and in other populations 1.5–5.8% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B11">11</xref>–<xref ref-type="bibr" rid="B14">14</xref>). Patients with loss-of-function <italic>MC4R</italic> mutations typically present with severe childhood obesity, hyperphagia, hyperinsulinemia, and increased linear growth (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B15">15</xref>). MC4R is a G-protein-coupled receptor (GPCR), which activates the stimulatory G protein (Gs), increases cAMP production and activates protein kinase A (PKA), leading to decreased food intake and increased energy expenditure (<xref ref-type="bibr" rid="B16">16</xref>). Lately, it has been suggested that in addition to Gs activation the MC4R downstream signaling includes several other pathways potentially important for weight regulation and that more patients than previously assumed may have functionally relevant genetic variants in <italic>MC4R</italic> (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>SIM1 and BDNF are transcription and neurotropic factors that control the neuronal differentiation of the hypothalamus and mutations in genes encoding these proteins have been associated with obesity (<xref ref-type="bibr" rid="B1">1</xref>). Recently, new obesity related genes involved in hypothalamic development or melanocortin pathway have been identified, such as <italic>ADCY3, MYT1L, POU3F2, GRPR</italic>, and <italic>LRP2</italic> (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B18">18</xref>–<xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>In recent years, advances have been made in the development of targeted therapy for patients with rare genetic disorders. Setmelanotide, a MC4R agonist, has shown promising results in promoting weight loss in patients with genetic loss-of-function defects in <italic>POMC, LEPR</italic>, and <italic>MC4R</italic> (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Genetic testing in patients with severe obesity is therefore important for the patients and their families, as it allows early detection of those at increased risk, optimal targeting of preventive measures and helps to identify patients likely to benefit from pharmacological treatment.</p>
<p>This study evaluated the prevalence and nature of genetic variants within the melanocortin pathway in patients affected by severe early-onset obesity. We have chosen to focus on the most severe end of the spectrum of obesity, namely on forms presenting already in early childhood, as they are more likely to be explained by genetic causes. We evaluated a Finnish cohort of 92 patients with severe childhood obesity and aimed to determine the rate and spectrum of rare pathogenic/likely pathogenic genetic variants in 24 genes linked to the melanocortin pathway or hypothalamic development.</p>
</sec>
<sec id="s2" sec-type="materials and methods">
<title>Materials and Methods</title>
<sec>
<title>Study Subjects</title>
<p>This study included altogether 92 children and adolescents with severe early-onset childhood obesity, as defined according to the Finnish growth standards (<xref ref-type="bibr" rid="B25">25</xref>) as height-adjusted weight &gt;60% before 10 years of age. All children were born to non-consanguineous parents. The patients were recruited at Children's Hospital at Helsinki University Hospital, Seinäjoki Central Hospital and Department of Children and Adolescents at Oulu University Hospital in Finland during years 2011–2017. All participating patients had been followed up by a pediatrician and patients diagnosed with an underlying endocrine or genetic disorder were excluded from the study (e.g., Prader–Willi syndrome, hypercortisolism, and hypothyroidism). Ethical approvals for the study were obtained from the research ethics committees of the Hospital District of Helsinki and Uusimaa, the Pirkanmaa Hospital District and the Northern Ostrobothnia Hospital District. Informed written consents were obtained from all the participants or from one of their guardians (for subjects aged &lt;18 years).</p>
<p>Hospital records were reviewed for clinical data. Anthropometric measurements including height, weight and waist circumference were measured during a study visit. BMI was calculated as weight divided by square height (kg/m<sup>2</sup>). Sex-and age-specific BMI Z-scores were derived based on the World Health Organization reference values (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/childgrowth/standards">www.who.int/childgrowth/standards</ext-link>). Blood samples were collected for genetic studies from all participants and from available first-degree family members (parents and siblings). Heights and weights were collected from the participating family members.</p>
</sec>
<sec>
<title>Genes in the Panel</title>
<p>We performed a literature search to identify genes related to the melanocortin pathway and the development of the hypothalamus (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B26">26</xref>–<xref ref-type="bibr" rid="B33">33</xref>). The 24 genes included in the panel were: (1) genes in which variants have previously been reported to cause or associate with obesity (<italic>ADCY3, BDNF, CPE, GRPR, LEP, LEPR, LRP2, MC3R, MC4R, MRAP2, MYT1L, NPY, NTRK2, PCSK1, POMC, SH2B1, SIM1, TUB</italic>) and (2) genes previously reported in animal models/linkage analysis/CNV studies to be involved in the melanocortin pathway or development of hypothalamus (<italic>ARNT2, ISL1, NEUROG3, OTP, OXT, POU3F2</italic>). Summary of the genes in the panel are presented in <xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>List of the obesity related genes included in the panel.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene symbol</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene name</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Function related to appetite control or hypothalamic development</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Relevance for human obesity</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ADCY3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adenylate cyclase 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in Gs signaling in hypothalamus, catalyzes the synthesis of cAMP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ARNT2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Aryl hydrocarbon receptor nuclear translocator 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates neuronal differentiation of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in the development of hypothalamus, animal models</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>BDNF</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brain-derived neurotrophic factor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates neuronal differentiation of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CPE</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Carboxypeptidase E</td>
<td align="left" colspan="1" rowspan="1" valign="top">Peptide processing enzyme, cleaves neuropeptides</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GRPR</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gastrin releasing peptide receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in the regulation of satiety</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ISL1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISL LIM homeobox 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in differentiation of hypothalamic neurons and expression of <italic>POMC</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in the development of hypothalamus, linkage analysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LEP</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Leptin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibits food intake</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LEPR</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Leptin receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Leptin receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">LDL receptor related protein 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increases leptin-induced STAT3 activation in POMC-expressing neurons</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC3R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Melanocortin-3 receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates energy homeostasis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Melanocortin-4 receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates appetite and energy homeostasis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MRAP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Melanocortin 2 receptor accessory protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates the function of melanocortin receptors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MYT1L</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myelin transcription factor 1 like</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription factor involved in development of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NEUROG3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenin 3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription factor involved in development of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in the development of hypothalamus, animal models</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NPY</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neuropeptide Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stimulates food intake</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NTRK2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotrophic tyrosine kinase receptor type 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates neuronal differentiation of hypothalamus, BDNF receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>OTP</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Orthopedia homeobox</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription factor involved in development of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in the development of hypothalamus, animal models</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>OXT</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oxytocin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in appetite regulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in hypothalamic circuit, animal models</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PCSK1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proprotein convertase subtilisin/kexin type 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in activation of processing of proteins and neuropeptide precursors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>POMC</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pro-opiomelanocortin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein precursor cleaved into alfa-MSH and binds to MC4R</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>POU3F2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">POU class 3 homeobox 2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription factor involved in development of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Role in development of hypothalamus, CNV studies</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SH2B1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Src homology 2 B adapter protein 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in modulation of leptin signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SIM1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Single-minded homolog 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates neuronal differentiation of hypothalamus</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>TUB</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tubby bipartite transcription factor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Involved in regulation of neuropeptides</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variants associated with obesity</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic presentation of the genes included in the panel.</p>
</caption>
<graphic xlink:href="fendo-11-00081-g0001"></graphic>
</fig>
</sec>
<sec>
<title>Genetic Analysis</title>
<p>Genomic DNA was isolated from obtained peripheral blood samples according to standard procedures. The probes for targeted exome sequencing were designed using SeqCap EZ Choice Library and NimbleDesign (Roche NimbleGen, United States). DNA capture and Next generation sequencing were performed at Oxford Genomics Center. Sequence reads were aligned to the reference human genome GRCh37. Variants were called using software Platypus software (version 0.8.1) and functionally annotated using Ensembl Variant Effector Predictor (VEP). Variant filtering was performed using VarAFT (version 2.13) (<xref ref-type="bibr" rid="B34">34</xref>). Non-synonymous exonic and splice site variants were considered. Variants with allele frequency higher than 0.5% (in Exome Aggregation Consortium (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>), the Genome Aggregation Database (<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org">http://gnomad.broadinstitute.org</ext-link>), 1,000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.internationalgenome.org">http://www.internationalgenome.org</ext-link>) and the Sequencing Initiative Suomi project (SISu) (<ext-link ext-link-type="uri" xlink:href="http://sisuproject.fi">http://sisuproject.fi</ext-link>) were filtered out. Possible pathogenicity of the variants was assessed using different variant prediction databases (Polyphen-2, SIFT, Combined Annotation Dependent Depletion (CADD) and MutationTaster2). We considered rare variants with allele frequency &lt;0.5% and variants predicted to be pathogenic by several <italic>in silico</italic> prediction tools, including a CADD score &gt;20, as likely pathogenic.</p>
<p>Sanger sequencing was performed to confirm the findings and to analyze parental and siblings' samples to determine inheritance pattern. Primers were designed using Primer3 software and PCR was performed using DreamTaq<sup>TM</sup> DNA Polymerase (Thermo Fischer Scientific) according to standard protocol. Chromatograms were analyzed with Sequencer v5.0 software. Primer sequences are available upon request.</p>
</sec>
<sec>
<title>Statistical Analyses</title>
<p>Results are reported as medians (interquartile range, IQR). Statistical analyses were performed with SPSS Statistical package (version 25.0.0.1).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec>
<title>Characteristics of the Study Cohort</title>
<p>The study included a total of 92 subjects (51% males). At the time of the study visit their median age was 13.7 years (IQR 10.6–16.8 years) and median BMI Z-score +4.0 (IQR + 3.4 to + 4.9). The study subjects fulfilled our inclusion criteria (height-adjusted weight &gt;60 %) at the median age of 6 years (IQR 4.5–7.0 years).</p>
</sec>
<sec>
<title>Targeted Exome Sequencing</title>
<p>On average 99.3% of bases in the coding exons were covered by at least 100 reads and the mean read depth of coverage was 755X. We found rare pathogenic/likely pathogenic variants in 7/92 (8%) of the study subjects and one rare variant of uncertain significance in one patient. The rare variants were in six of the 24 genes in the panel, with variants in the <italic>MC4R</italic> gene being the most common finding (3/92). The genetic and clinical features of the patients with the rare variants are presented below and summarized in <xref ref-type="table" rid="T2">Table 2</xref>. The prediction values of the identified variants are presented in <xref ref-type="table" rid="T3">Table 3</xref>.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Genetic and clinical characteristics of the patients with rare genetic variants (MAF &lt; 0.5%), reference human genome GRCh37.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Patient</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Chromosome position</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Transcript</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>cDNA</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Protein</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Inheritance</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>BMI (<italic>Z</italic>-score)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Clinical features</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frameshift deletion</td>
<td align="left" colspan="1" rowspan="1" valign="top">18:58039275 A&gt;-</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_005912</td>
<td align="left" colspan="1" rowspan="1" valign="top">308delT</td>
<td align="left" colspan="1" rowspan="1" valign="top">V103Afs5*</td>
<td align="left" colspan="1" rowspan="1" valign="top">Maternal</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperphagia, type 2 diabetes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frameshift deletion</td>
<td align="left" colspan="1" rowspan="1" valign="top">18:58039275 A&gt;-</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_005912</td>
<td align="left" colspan="1" rowspan="1" valign="top">308delT</td>
<td align="left" colspan="1" rowspan="1" valign="top">V103Afs5*</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>De novo</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperphagia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">18:58039248 G&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_005912</td>
<td align="left" colspan="1" rowspan="1" valign="top">335C&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">T112M</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.1</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ADCY3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">2:25042908 C&gt;G</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_004036</td>
<td align="left" colspan="1" rowspan="1" valign="top">3328G&gt;C</td>
<td align="left" colspan="1" rowspan="1" valign="top">G1110R</td>
<td align="left" colspan="1" rowspan="1" valign="top">Maternal</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin resistance, asthma, depression</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MYT1L</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">2:1893113 C&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_001303052</td>
<td align="left" colspan="1" rowspan="1" valign="top">2420G&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">R807Q</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Behavioral problems</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">6</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ISL1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">5:50689433 A&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_002202</td>
<td align="left" colspan="1" rowspan="1" valign="top">1039A&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">I347F</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.8</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">2:170062653 C&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_004525</td>
<td align="left" colspan="1" rowspan="1" valign="top">7436G&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">R2479I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Maternal</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.8</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">2:170038731 T&gt;C</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_004525</td>
<td align="left" colspan="1" rowspan="1" valign="top">9944A&gt;G</td>
<td align="left" colspan="1" rowspan="1" valign="top">N3315S</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin resistance, hypothyroidism, depression</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GRPR</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense variant</td>
<td align="left" colspan="1" rowspan="1" valign="top">X:16142335C&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_005314</td>
<td align="left" colspan="1" rowspan="1" valign="top">259C&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">L87M</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin resistance, hypothyroidism, depression</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>NA, data not available</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Prediction values of the rare genetic variants detected in the obesity cohort.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Variant</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Polyphen-2</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>SIFT</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>CADD</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>MutationTaster</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">V103Afs5*</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not applicable</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not applicable</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not applicable</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MC4R</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">T112M</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerate</td>
<td align="left" colspan="1" rowspan="1" valign="top">8.9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Polymorphism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ADCY3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">G1110R</td>
<td align="left" colspan="1" rowspan="1" valign="top">Probably damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deleterious</td>
<td align="left" colspan="1" rowspan="1" valign="top">34.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MYT1L</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">R807Q</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerate</td>
<td align="left" colspan="1" rowspan="1" valign="top">23.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ISL1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">I347F</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deleterious</td>
<td align="left" colspan="1" rowspan="1" valign="top">23.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">R2479I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Probably damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deleterious</td>
<td align="left" colspan="1" rowspan="1" valign="top">34.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N3315S</td>
<td align="left" colspan="1" rowspan="1" valign="top">Probably damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deleterious</td>
<td align="left" colspan="1" rowspan="1" valign="top">25.6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GRPR</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">L87M</td>
<td align="left" colspan="1" rowspan="1" valign="top">Probably damaging</td>
<td align="left" colspan="1" rowspan="1" valign="top">Deleterious</td>
<td align="left" colspan="1" rowspan="1" valign="top">25.6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Disease causing</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s4">
<title>Rare Exonic Variants and Associated Phenotypes</title>
<sec>
<title><italic>MC4R</italic> Variants</title>
<p>In <italic>MC4R</italic> (NM_005912) we identified altogether 2 variants. The first was a novel heterozygous frameshift deletion c.308delT present in two unrelated patients. The frameshift variant was confirmed by Sanger sequencing (<xref ref-type="fig" rid="F2">Figure 2</xref>). The deletion causes a frameshift at amino acid 103 (p.V103Afs5<sup>*</sup>) and introduces four new amino acids resulting in a stop codon in the region of the second transmembrane domain, leading to a significantly truncated protein of only 107 amino acids compared to the normal 332-amino-acid MC4R (<xref ref-type="fig" rid="F3">Figure 3</xref>). The variant is absent in all databases (ExAC, gnomAD, 1,000 Genomes, SISu). MutationTaster2 predicted the deletion as disease-causing.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Chromatograms of Sanger sequence analysis of <italic>MC4R</italic> showing a heterozygous frameshift deletion (p.V103Afs5*) in two index patients with monogenic obesity <bold>(A)</bold> and the normal MC4R sequence <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fendo-11-00081-g0002"></graphic>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Schematic presentation of the MC4R protein and the location of the frameshift variant (p.V103Afs5*) and the missense variant (p.T112M) identified in patients with obesity.</p>
</caption>
<graphic xlink:href="fendo-11-00081-g0003"></graphic>
</fig>
<p>The pedigrees of the two unrelated families with the <italic>MC4R</italic> frameshift variant are presented in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Pedigrees of the families with MC4R frameshift variant (p.V103Afs5*). Square = male, circle = female, +/– heterozygote carrier, –/– wildtype. Black square/circle = obesity, gray square/circle = overweight, white square/circle = normal weight.</p>
</caption>
<graphic xlink:href="fendo-11-00081-g0004"></graphic>
</fig>
<p>Patient 1 is a 20-year-old female with normal birth measurements: weight 3.6 kg and length 48 cm. She presented with severe obesity already at the age of 1 year with weight 17.8 kg and height 81.5 cm (BMI Z-score + 5.8). Presently at age 20 years, her weight is 121 kg, height 170.5 cm (BMI 44) and waist circumference 133 cm. She also has type 2 diabetes and hyperphagia. Her mother, heterozygous for the same mutation, presented with obesity in childhood and overweight during adulthood. The mutation-negative father had normal weight during childhood. The index patient's 2.5-year-old son also carries the same frameshift deletion. He presented with overweight at age 9 months with a BMI Z-score of + 2.9. Currently, his BMI Z-score is +1.8 and he requires close monitoring for pronounced hyperphagia.</p>
<p>Patient 2 is an 18-year-old male with BMI 35 (weight 106 kg and height 173.5 cm) and waist circumference 110 cm. His birth measurements were normal (3.4 kg and 50.5 cm) and he presented with obesity at the age of 3 years measuring 18.5 kg and 93.5 cm (BMI Z-score +3.9). He also presented with hyperphagia. The variant was <italic>de novo</italic> as his overweight parents and normal weight sister did not have the variant.</p>
<p>The other identified <italic>MC4R</italic> variant is a previously reported heterozygous missense variant, c.335C&gt;T (p.T112M) (<xref ref-type="fig" rid="F3">Figure 3</xref>) in Patient 3; a 12-year-old boy with normal birth measurements (3.5 kg and 50 cm). He presented with obesity at age 4 years measuring 29.2 kg and 114.3 cm (BMI Z-score +4.5). Presently at the age of 12 years, his weight is 114.4 kg and height 177.1 cm (BMI Z-score +4.1). He had accelerated linear growth with growth velocity of 12 cm/year at the age of 5 years, leading to height-for-age Z-score +4.1 at age 12 years. His mother's height was 163 cm and father's 183 cm. The patient's mother with obesity did not harbor the variant. No DNA was available from the other family members. The allele frequency of the variant is 0.09% in all populations in gnomAD, 0.2% in the Finnish population in gnomAD and 0.18% in SISu.</p>
</sec>
<sec>
<title><italic>ADCY3</italic> Missense Variant</title>
<p>We identified a heterozygous missense variant in <italic>ADCY3</italic> (c.3328G&gt;C, p.G1110R) in Patient 4; a 16-year-old female with a BMI Z-score of +4.8, insulin resistance, asthma and depression. She had normal birth measurements (3.25 kg and 51 cm). She presented with obesity already at the age of 1.5 years measuring 16.3 kg and 86.4 cm (BMI Z-score + 3.6). The patient's mother (BMI 35) also carried the same variant. The father's DNA was not available. According to gnomAD, the variant is found in 1/3474 in the Finnish population.</p>
</sec>
<sec>
<title><italic>MYT1L</italic> Missense Variant</title>
<p>We detected a heterozygous missense variant in <italic>MYT1L</italic> (c.2420G&gt;A, p.R807Q) in Patient 5; a 12-year-old girl with a BMI Z-score of + 3.8. She presented with aggressive behavior and reading problems. The variant was not found in her normal-weight mother; DNA of the normal-weight father was not available. The allele frequency of the variant is 0.01% in all populations in gnomAD, 0.1% in the Finnish population in gnomAD and 0.1% in SISu.</p>
</sec>
<sec>
<title><italic>ISL1</italic> Missense Variant</title>
<p>We found a heterozygous missense variant in <italic>ISL1</italic> (c.1039A&gt;T, p.I347F) in Patient 6; a 9-year-old girl with a BMI Z-score of + 2.8. The patient had normal development and no endocrinological abnormalities. Her mother (BMI 39) was also a carrier of the variant but her normal-weight father was not. The variant is found in 5/25038 (all heterozygotes) in the Finnish population in gnomAD and the allele frequency is 0.03 % in SISu.</p>
</sec>
<sec>
<title><italic>LRP2</italic> Missense Variants</title>
<p>We identified two heterozygous missense variants in <italic>LRP2</italic>. The first variant (c.7436G&gt;T, p.R2479I) was found in Patient 7, a 19-year-old boy with a BMI Z-score of + 2.8, and in his mother (BMI 39). The variant is not found in any of the above-mentioned databases.</p>
<p>The second variant in <italic>LRP2</italic> (c.9944A&gt;G, p.N3315S) was detected in Patient 8; a 16-year-old boy with a BMI Z-score of + 4.3, insulin resistance, fatty liver, hypothyroidism and severe depression. The patient had an overweight mother and a normal-weight father, but parental DNAs were unavailable. The variant is not found in the Finnish population in gnomAD or in SISu, but it is found in 2/24956 (both heterozygotes) in African population in gnomAD.</p>
</sec>
<sec>
<title><italic>GRPR</italic> Missense Variant</title>
<p>In Patient 8, harboring an <italic>LRP2</italic> variant (p.N3315S), we also identified a hemizygous missense variant (c.259C&gt;A, p.L87M) in <italic>GRPR</italic>. This variant is present with allele frequency 0.02% in the Finnish population in gnomAD and SISu.</p>
</sec>
</sec>
<sec id="s5" sec-type="discussion">
<title>Discussion</title>
<p>Recent advances in genetic methodology have enabled identification of novel genetic factors that may contribute to obesity. Such discoveries have increased our understanding of the significance of various components involved in the hypothalamic circuit regulating appetite and energy expenditure. By using targeted exome sequencing, we identified several rare exonic variants in genes related to the leptin-melanocortin pathway and hypothalamic development in a large cohort of Finnish patients with severe childhood-onset obesity. Altogether 7 of the 92 studied subjects (8%) harbored at least one rare and pathogenic/likely pathogenic variant in the studied 24 genes, suggesting that a significant proportion of severe childhood-onset obesity could be related to genetic defects within the hypothalamic circuit.</p>
<p>The prevalence of monogenic obesity varies with ethnicity and consanguinity. Close consanguinity is rare in the Finnish population (<xref ref-type="bibr" rid="B35">35</xref>) and there were no consanguineous families in our cohort. We did not detect any pathogenic variants in LEPR, LEP, POMC, and PCSK1 genes. Patients with these gene defects often have very early and rapid weight gain and associated endocrinopathies. It is therefore possible, that such patients may have been identified earlier by pediatricians and thus excluded from our study focusing on obesity of unknown etiology.</p>
<p>The prevalence of pathogenic variants in <italic>MC4R</italic> in our cohort was 2% (2/92), which is comparable to previous reports (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B14">14</xref>). The patients in our study with the novel <italic>MC4R</italic> frameshift deletion had severe childhood obesity and hyperphagia. The frameshift deletion is considered pathogenic as it leads to a significantly truncated protein and its functional consequences on the receptor function are likely to be considerable.</p>
<p>Additionally, we detected a previously identified rare heterozygous missense variant (p.T112M) in <italic>MC4R</italic>. Our patient presented with childhood obesity, markedly increased linear growth and tall stature during childhood. <italic>MC4R</italic> deficiency has been associated with accelerated linear growth and increased final height (<xref ref-type="bibr" rid="B15">15</xref>). In contrast, we did not observe increased final height or linear growth in the patients with the <italic>MC4R</italic> frameshift variant. The missense variant is not shown to be pathogenic according to prediction tools and the variant has previously been reported as having normal Gs signaling according to <italic>in vitro</italic> functional studies (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B36">36</xref>). However, the variant has been described as a biased signaling variant that leads to decreased ERK1/2 activation. <italic>MC4R</italic> variants that alter the ERK1/2 signaling have been suggested to be involved in regulation of food intake (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). We considered this variant to be of uncertain significance as further studies are needed to explore the impact of non-Gs signaling <italic>MC4R</italic> variants on weight regulation.</p>
<p><italic>ADCY3</italic> encodes adenylyl cyclase 3, which localizes at the cilia of paraventricular nucleus in the hypothalamus and is involved in the Gs signaling. Previous studies have shown that <italic>Adcy3</italic> heterozygous null mice present with obesity, insulin resistance and increased adiposity (<xref ref-type="bibr" rid="B37">37</xref>). A glucagon-like peptide-1 analog, liraglutide, has been shown to increase the expression of hepatic <italic>Adcy3</italic> in obese and diabetic mice and the <italic>Adcy3</italic> activation may partly account for the reduction of blood glucose levels and bodyweight (<xref ref-type="bibr" rid="B38">38</xref>). Furthermore, previous studies have identified homozygous mutations in <italic>ADCY3</italic> in children with severe obesity (<xref ref-type="bibr" rid="B33">33</xref>), and an <italic>ADCY3</italic> variant has been associated with increased risk of obesity and type 2 diabetes in homozygous individuals and to a lesser degree in heterozygous carriers (<xref ref-type="bibr" rid="B18">18</xref>). The patient in our study was heterozygous for a non-synonymous <italic>ADCY3</italic> variant with a high CADD score. She had severe obesity and insulin resistance and her mother, harboring the same variant, also presented with obesity. The <italic>ADCY3</italic> variant was predicted disease causing and is likely to play a role in the obesity and insulin resistance in our patient.</p>
<p><italic>MYT1L</italic> is expressed in the brain and involved in the development of neuroendocrine hypothalamus. Several <italic>MYT1L</italic> mutations have been identified in patients with obesity, intellectual disability, developmental delay, autistic features and behavioral problems (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Loss of <italic>MYT1L</italic> in zebrafish was related to altered hypothalamic development and loss of oxytocin (<italic>OXT</italic>) in the neuroendocrine preoptic area. <italic>MYT1L</italic> was demonstrated to be part of the melanocortin pathway, functioning downstream of <italic>SIM1</italic>, and <italic>OXT</italic> was recognized as a potential treatment target (<xref ref-type="bibr" rid="B19">19</xref>). We have previously described a Finnish patient with a frameshift deletion in <italic>MYT1L</italic> presenting with obesity, intellectual disability and developmental delay (<xref ref-type="bibr" rid="B20">20</xref>). The patient in this study with the presumed <italic>de novo MYT1L</italic> variant had severe obesity, aggressive behavior and learning difficulties. Although our patient did not present with marked developmental delay or intellectual disability, her aggressive behavior, learning difficulties and the early-onset obesity are likely to be related to the identified <italic>MYT1L</italic> variant.</p>
<p>The Insulin gene enhance protein ISL-1, encoded by <italic>ISL1</italic>, is a transcription factor involved in many developmental processes. Mice and zebrafish experiments have shown that <italic>Isl1</italic> is expressed in the developing brain, regulates the differentiation of hypothalamic neurons and is important for the expression of <italic>Pomc</italic> in the hypothalamus. Inactivation of <italic>Isl1</italic> in Pomc neurons reduces the expression of <italic>Pomc</italic> and leads to obesity (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B40">40</xref>). A linkage analysis in French families with morbid obesity showed linkage between <italic>ISL1</italic> and BMI and leptin (<xref ref-type="bibr" rid="B41">41</xref>). Variants in <italic>ISL1</italic> have previously been associated with congenital heart defects (<xref ref-type="bibr" rid="B42">42</xref>), but to our knowledge, no mutations in <italic>ISL1</italic> have been reported in monogenic obesity. The <italic>ISL1</italic> missense variant found in our study segregated with the obesity phenotype in the family and was predicted disease causing. The role of <italic>ISL1</italic> in the development of obesity and the functional relevance of the variant require further studies.</p>
<p>Low-density lipoprotein receptor 2 gene (<italic>LRP2</italic>), encodes an endocytic receptor, LRP2 or megalin. LRP2 has many ligands in various tissues. LRP2 increases leptin-induced STAT3 activation in POMC-expressing neurons in hypothalamus and inhibits food intake. STAT3 signaling is reduced in the absence of functional LRP2 (<xref ref-type="bibr" rid="B22">22</xref>). <italic>LRP2</italic> has been associated with monogenic obesity (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Here we identified two patients with rare heterozygous variants in <italic>LRP2</italic>; one novel missense variant (p.R2479I), and another rare missense variant (p.N3315S), neither one has previously been found in the Finnish population. Both <italic>LRP2</italic> variants were predicted disease-causing. More studies are required to explore the functional significance of these <italic>LRP2</italic> variants.</p>
<p><italic>GRPR</italic>, encoding gastrin-releasing peptide receptor, is an X-linked 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. <italic>GRPR</italic> is expressed in several tissues, including the brain and is involved in the regulation of satiety. A previous study identified in five patients with obesity heterozygous or hemizygous mutations in <italic>GRPR</italic> that were predicted functionally relevant (<xref ref-type="bibr" rid="B5">5</xref>). The hemizygous <italic>GRPR</italic> variant (p.L87M) identified in our study was also detected in a boy with severe obesity by Serra-Juhe et al. (<xref ref-type="bibr" rid="B5">5</xref>). In their co-expression analysis <italic>GRPR</italic> showed clear enrichment of co-expression with genes from the melanocortin pathway (<xref ref-type="bibr" rid="B5">5</xref>). Our patient presented with early-onset obesity, insulin resistance, fatty liver, hypothyroidism, and severe depression. Interestingly, <italic>GRPR</italic> has also been implicated in psychiatric disorders like depression (<xref ref-type="bibr" rid="B43">43</xref>), suggesting that the hemizygous <italic>GRPR</italic> variant contributes to the severe depression seen in our patient. In addition, our patient also harbors a rare variant (p.N3315S) in the <italic>LRP2</italic> gene and it therefore remains uncertain how each of the two variants contribute to the phenotype.</p>
<p>Next generation sequencing is an important tool in identifying genetic causes in monogenic obesity. Targeted exome sequencing provides several advantages compared to whole-exome sequencing; it is cost-effective, has high quality with high read depth and coverage, data interpretation is easier as the number of genes is limited, and chance of incidental findings is minimal. Its weakness is the limited number of genes included in panel. Because of this methodological limitation we may have missed variants in novel genes that were not included in the gene panel but still contribute to hypothalamic function. Another limitation in our study is the lack of available family members for genetic testing in some instances and therefore interpretation of the pathogenicity of the identified variants was more challenging. Further, our study did not include any functional evaluations of the genetic findings and therefore the contribution of some of the variants to the obesity development remains uncertain. However, we only considered rare exonic variants with allele frequency &lt;0.5% and variants predicted to be pathogenic by several <italic>in silico</italic> prediction tools, including a high CADD score as likely pathogenic.</p>
<p>In conclusion, we report rare pathogenic/likely pathogenic variants in genes involved in hypothalamic circuit in 7/92 (8%) of patients with early-onset obesity. Our results support the role of hypothalamic melanocortin pathway in the development of obesity. Further studies are required to explore the clinical relevance of the rare genetic variants. Novel therapies targeting specific genetic defects are under development and may offer future treatment modalities in patients with monogenic obesity.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>Data cannot be shared publicly because the data consists of sensitive patient data. More specifically the data consists of individual clinical data and individual genotypes for young children. Data are available from the Helsinki University Hospital's Institutional Data Access/Ethics Committee for researchers who meet the criteria for access to confidential data. Data availability contacts: Outi Mäkitie, <email>outi.makitie@helsinki.fi</email>.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>PL, TM, HV, ML-N, MP, and OM: study design. PL, TM, HV, PT, and ML-N: data collection. PL, AK, MP, and OM: data analysis and data interpretation. PL, RM, AK, MP, and OM: drafting of manuscript. All authors contributed to manuscript revision and approved the final version.</p>
<sec>
<title>Conflict of Interest</title>
<p>OM declares consultancy to Kyowa Kirin, Alexion, and Sandoz. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>We thank all the patients and their family members for participating in the study. We thank RN Päivi Turunen for help with data collection.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was financially supported by the Academy of Finland; Sigrid Jusélius Foundation; Foundation for Pediatric Research; Folkhälsan Research Foundation; Päivikki ja Sakari Sohlberg Foundation; Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns minne; Emil Aaltonen Foundation; Swedish Research Council; Novo Nordisk Foundation; University of Helsinki through the Doctoral Program in Clinical Research; Helsinki University Hospital research funds.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da</surname><given-names>Fonseca ACP</given-names></name><name><surname>Mastronardi</surname><given-names>C</given-names></name><name><surname>Johar</surname><given-names>A</given-names></name><name><surname>Arcos-Burgos</surname><given-names>M</given-names></name><name><surname>Paz-Filho</surname><given-names>G</given-names></name></person-group>. <article-title>Genetics of non-syndromic childhood obesity and the use of high-throughput DNA sequencing technologies</article-title>. <source/>J Diabetes Complicat. (<year>2017</year>) <volume>31</volume>:<fpage>1549</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdiacomp.2017.04.026</pub-id><pub-id pub-id-type="pmid">28735903</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locke</surname><given-names>AE</given-names></name><name><surname>Kahali</surname><given-names>B</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Justice</surname><given-names>AE</given-names></name><name><surname>Pers</surname><given-names>TH</given-names></name><name><surname>Day</surname><given-names>FR</given-names></name><etal></etal></person-group>. <article-title>Genetic studies of body mass index yield new insights for obesity biology</article-title>. <source/>Nature. (<year>2015</year>) <volume>518</volume>:<fpage>197</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1038/nature14177</pub-id><pub-id pub-id-type="pmid">25673413</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yengo</surname><given-names>L</given-names></name><name><surname>Sidorenko</surname><given-names>J</given-names></name><name><surname>Kemper</surname><given-names>KE</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Wood</surname><given-names>AR</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><etal></etal></person-group>. <article-title>Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry</article-title>. <source/>Hum Mol Genet. (<year>2018</year>) <volume>27</volume>:<fpage>3641</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddy271</pub-id><pub-id pub-id-type="pmid">30124842</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Viljakainen</surname><given-names>H</given-names></name><name><surname>Loid</surname><given-names>P</given-names></name><name><surname>Mustila</surname><given-names>T</given-names></name><name><surname>Pekkinen</surname><given-names>M</given-names></name><name><surname>Armenio</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Copy number variants are enriched in individuals with early-onset obesity and highlight novel pathogenic pathways</article-title>. <source/>J Clin Endocrinol Metab. (<year>2017</year>) <volume>102</volume>:<fpage>3029</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2017-00565</pub-id><pub-id pub-id-type="pmid">28605459</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra-Juhe</surname><given-names>C</given-names></name><name><surname>Martos-Moreno</surname><given-names>GA</given-names></name><name><surname>Bou</surname><given-names>de Pieri F</given-names></name><name><surname>Flores</surname><given-names>R</given-names></name><name><surname>Gonzalez</surname><given-names>JR</given-names></name><name><surname>Rodriguez-Santiago</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Novel genes involved in severe early-onset obesity revealed by rare copy number and sequence variants</article-title>. <source/>PLoS Genet. (<year>2017</year>) <volume>13</volume>:<fpage>e1006657</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1006657</pub-id><pub-id pub-id-type="pmid">28489853</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Bochukova</surname><given-names>EG</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Lindsay</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity</article-title>. <source/>Nat Genet. (<year>2013</year>) <volume>45</volume>:<fpage>513</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2607</pub-id><pub-id pub-id-type="pmid">23563609</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra-Juhe</surname><given-names>C</given-names></name><name><surname>Martos-Moreno</surname><given-names>GA</given-names></name><name><surname>Bou</surname><given-names>de Pieri F</given-names></name><name><surname>Flores</surname><given-names>R</given-names></name><name><surname>Chowen</surname><given-names>JA</given-names></name><name><surname>Perez-Jurado</surname><given-names>LA</given-names></name><etal></etal></person-group>. <article-title>Heterozygous rare genetic variants in non-syndromic early-onset obesity</article-title>. <source/>Int J Obes. (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41366-019-0357-5</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">30926952</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendricks</surname><given-names>AE</given-names></name><name><surname>Bochukova</surname><given-names>EG</given-names></name><name><surname>Marenne</surname><given-names>G</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Atanassova</surname><given-names>N</given-names></name><name><surname>Bounds</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Rare variant analysis of human and rodent obesity genes in individuals with severe childhood obesity</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>4394</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-03054-8</pub-id><pub-id pub-id-type="pmid">28663568</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collet</surname><given-names>TH</given-names></name><name><surname>Dubern</surname><given-names>B</given-names></name><name><surname>Mokrosinski</surname><given-names>J</given-names></name><name><surname>Connors</surname><given-names>H</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Mendes</surname><given-names>de Oliveira E</given-names></name><etal></etal></person-group>. <article-title>Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency</article-title>. <source/>Mol Metab. (<year>2017</year>) <volume>6</volume>:<fpage>1321</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmet.2017.06.015</pub-id><pub-id pub-id-type="pmid">29031731</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valli-Jaakola</surname><given-names>K</given-names></name><name><surname>Lipsanen-Nyman</surname><given-names>M</given-names></name><name><surname>Oksanen</surname><given-names>L</given-names></name><name><surname>Hollenberg</surname><given-names>AN</given-names></name><name><surname>Kontula</surname><given-names>K</given-names></name><name><surname>Bjorbaek</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese finnish children and adults</article-title>. <source/>J Clin Endocrinol Metab. (<year>2004</year>) <volume>89</volume>:<fpage>940</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2003-031182</pub-id><pub-id pub-id-type="pmid">14764818</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooqi</surname><given-names>IS</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Yeo</surname><given-names>GS</given-names></name><name><surname>Lank</surname><given-names>EJ</given-names></name><name><surname>Cheetham</surname><given-names>T</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name></person-group>. <article-title>Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene</article-title>. <source/>N Engl J Med. (<year>2003</year>) <volume>348</volume>:<fpage>1085</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa022050</pub-id><pub-id pub-id-type="pmid">12646665</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinendorst</surname><given-names>L</given-names></name><name><surname>Massink</surname><given-names>MPG</given-names></name><name><surname>Cooiman</surname><given-names>MI</given-names></name><name><surname>Savas</surname><given-names>M</given-names></name><name><surname>van der Baan-Slootweg</surname><given-names>OH</given-names></name><name><surname>Roelants</surname><given-names>RJ</given-names></name><etal></etal></person-group>. <article-title>Genetic obesity: next-generation sequencing results of 1230 patients with obesity</article-title>. <source/>J Med Genet. (<year>2018</year>) <volume>55</volume>:<fpage>578</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105315</pub-id><pub-id pub-id-type="pmid">29970488</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinci</surname><given-names>A</given-names></name><name><surname>Turkkahraman</surname><given-names>D</given-names></name><name><surname>Tekedereli</surname><given-names>I</given-names></name><name><surname>Ozer</surname><given-names>L</given-names></name><name><surname>Evren</surname><given-names>B</given-names></name><name><surname>Sahin</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Novel mutations in obesity-related genes in turkish children with non-syndromic early onset severe obesity: a multicentre study</article-title>. <source/>J Clin Res Pediatr Endocrinol. (<year>2019</year>) <volume>11</volume>:<fpage>341</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4274/jcrpe.galenos.2019.2019.0021</pub-id><pub-id pub-id-type="pmid">30991789</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>MC</given-names></name><name><surname>Chesi</surname><given-names>A</given-names></name><name><surname>McCormack</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Weaver</surname><given-names>B</given-names></name><name><surname>McDonald</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Characterization of rare variants in MC4R in African American and latino children with severe early-onset obesity</article-title>. <source/>J Clin Endocrinol Metab. (<year>2019</year>) <volume>104</volume>:<fpage>2961</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2018-02657</pub-id><pub-id pub-id-type="pmid">30811542</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname><given-names>CE</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Greenfield</surname><given-names>JR</given-names></name><name><surname>Henning</surname><given-names>E</given-names></name><name><surname>van der Klaauw</surname><given-names>AA</given-names></name><name><surname>Blackwood</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion</article-title>. <source/>J Clin Endocrinol Metab. (<year>2011</year>) <volume>96</volume>:<fpage>E181</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-1369</pub-id><pub-id pub-id-type="pmid">21047921</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhnen</surname><given-names>P</given-names></name><name><surname>Krude</surname><given-names>H</given-names></name><name><surname>Biebermann</surname><given-names>H</given-names></name></person-group>. <article-title>Melanocortin-4 receptor signalling: importance for weight regulation and obesity treatment</article-title>. <source/>Trends Mol Med. (<year>2019</year>) <volume>25</volume>:<fpage>136</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2018.12.002</pub-id><pub-id pub-id-type="pmid">30642682</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>YX</given-names></name></person-group>. <article-title>Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene</article-title>. <source/>Int J Biol Sci. (<year>2014</year>) <volume>10</volume>:<fpage>1128</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.10359</pub-id><pub-id pub-id-type="pmid">25332687</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Moltke</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>MK</given-names></name><name><surname>Dalby</surname><given-names>M</given-names></name><name><surname>Vitting-Seerup</surname><given-names>K</given-names></name><name><surname>Kern</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes</article-title>. <source/>Nat Genet. (<year>2018</year>) <volume>50</volume>:<fpage>172</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-017-0022-7</pub-id><pub-id pub-id-type="pmid">29311636</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchet</surname><given-names>P</given-names></name><name><surname>Bebin</surname><given-names>M</given-names></name><name><surname>Bruet</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Thompson</surname><given-names>ML</given-names></name><name><surname>Duban-Bedu</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus</article-title>. <source/>PLoS Genet. (<year>2017</year>) <volume>13</volume>:<fpage>e1006957</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1006957</pub-id><pub-id pub-id-type="pmid">28859103</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loid</surname><given-names>P</given-names></name><name><surname>Makitie</surname><given-names>R</given-names></name><name><surname>Costantini</surname><given-names>A</given-names></name><name><surname>Viljakainen</surname><given-names>H</given-names></name><name><surname>Pekkinen</surname><given-names>M</given-names></name><name><surname>Makitie</surname><given-names>O</given-names></name></person-group>. <article-title>A novel MYT1L mutation in a patient with severe early-onset obesity and intellectual disability</article-title>. <source/>Am J Med Genet A. (<year>2018</year>) <volume>176</volume>:<fpage>1972</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.40370</pub-id><pub-id pub-id-type="pmid">30055078</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasher</surname><given-names>PR</given-names></name><name><surname>Schertz</surname><given-names>KE</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Annunziata</surname><given-names>S</given-names></name><name><surname>Ballesta-Martinez</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Small 6q16</article-title>.1 deletions encompassing POU3F2 cause susceptibility to obesity and variable developmental delay with intellectual disability. <source/>Am J Hum Genet. (<year>2016</year>) <volume>98</volume>:<fpage>363</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.12.014</pub-id><pub-id pub-id-type="pmid">26833329</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paz-Filho</surname><given-names>G</given-names></name><name><surname>Boguszewski</surname><given-names>MC</given-names></name><name><surname>Mastronardi</surname><given-names>CA</given-names></name><name><surname>Patel</surname><given-names>HR</given-names></name><name><surname>Johar</surname><given-names>AS</given-names></name><name><surname>Chuah</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Whole exome sequencing of extreme morbid obesity patients: translational implications for obesity and related disorders</article-title>. <source/>Genes. (<year>2014</year>) <volume>5</volume>:<fpage>709</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.3390/genes5030709</pub-id><pub-id pub-id-type="pmid">25158045</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhnen</surname><given-names>P</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Wiegand</surname><given-names>S</given-names></name><name><surname>Blankenstein</surname><given-names>O</given-names></name><name><surname>Gottesdiener</surname><given-names>K</given-names></name><name><surname>Martini</surname><given-names>LL</given-names></name><etal></etal></person-group>. <article-title>Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist</article-title>. <source/>N Engl J Med. (<year>2016</year>) <volume>375</volume>:<fpage>240</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1512693</pub-id><pub-id pub-id-type="pmid">27468060</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Biebermann</surname><given-names>H</given-names></name><name><surname>Farooqi</surname><given-names>IS</given-names></name><name><surname>Van der Ploeg</surname><given-names>L</given-names></name><name><surname>Wolters</surname><given-names>B</given-names></name><name><surname>Poitou</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency</article-title>. <source/>Nat Med. (<year>2018</year>) <volume>24</volume>:<fpage>551</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0015-9</pub-id><pub-id pub-id-type="pmid">29736023</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saari</surname><given-names>A</given-names></name><name><surname>Sankilampi</surname><given-names>U</given-names></name><name><surname>Hannila</surname><given-names>ML</given-names></name><name><surname>Kiviniemi</surname><given-names>V</given-names></name><name><surname>Kesseli</surname><given-names>K</given-names></name><name><surname>Dunkel</surname><given-names>L</given-names></name></person-group>. <article-title>New finnish growth references for children and adolescents aged 0 to 20 years: length/height-for-age, weight-for-length/height, and body mass index-for-age</article-title>. <source/>Ann Med. (<year>2011</year>) <volume>43</volume>:<fpage>235</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3109/07853890.2010.515603</pub-id><pub-id pub-id-type="pmid">20854213</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsters</surname><given-names>SI</given-names></name><name><surname>Goldstone</surname><given-names>AP</given-names></name><name><surname>Buxton</surname><given-names>JL</given-names></name><name><surname>Zekavati</surname><given-names>A</given-names></name><name><surname>Sosinsky</surname><given-names>A</given-names></name><name><surname>Yiorkas</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>Truncating Homozygous mutation of carboxypeptidase E (CPE) in a morbidly obese female with type 2 diabetes mellitus, intellectual disability and hypogonadotrophic hypogonadism</article-title>. <source/>PLoS ONE. (<year>2015</year>) <volume>10</volume>:<fpage>e0131417</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0131417</pub-id><pub-id pub-id-type="pmid">26120850</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandrappa</surname><given-names>S</given-names></name><name><surname>Raimondo</surname><given-names>A</given-names></name><name><surname>Cali</surname><given-names>AM</given-names></name><name><surname>Keogh</surname><given-names>JM</given-names></name><name><surname>Henning</surname><given-names>E</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Rare variants in single-minded 1 (SIM1) are associated with severe obesity</article-title>. <source/>J Clin Invest. (<year>2013</year>) <volume>123</volume>:<fpage>3042</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1172/JCI68016</pub-id><pub-id pub-id-type="pmid">23778139</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelling</surname><given-names>M</given-names></name><name><surname>Anthwal</surname><given-names>N</given-names></name><name><surname>McNay</surname><given-names>D</given-names></name><name><surname>Gradwohl</surname><given-names>G</given-names></name><name><surname>Leiter</surname><given-names>AB</given-names></name><name><surname>Guillemot</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Differential requirements for neurogenin 3 in the development of POMC and NPY neurons in the hypothalamus</article-title>. <source/>Dev Biol. (<year>2011</year>) <volume>349</volume>:<fpage>406</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2010.11.007</pub-id><pub-id pub-id-type="pmid">21074524</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthwal</surname><given-names>N</given-names></name><name><surname>Pelling</surname><given-names>M</given-names></name><name><surname>Claxton</surname><given-names>S</given-names></name><name><surname>Mellitzer</surname><given-names>G</given-names></name><name><surname>Collin</surname><given-names>C</given-names></name><name><surname>Kessaris</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Conditional deletion of neurogenin-3 using Nkx2</article-title>.1iCre results in a mouse model for the central control of feeding, activity and obesity. <source/>Dis Model Mech. (<year>2013</year>) <volume>6</volume>:<fpage>1133</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.011916</pub-id><pub-id pub-id-type="pmid">23649822</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moir</surname><given-names>L</given-names></name><name><surname>Bochukova</surname><given-names>EG</given-names></name><name><surname>Dumbell</surname><given-names>R</given-names></name><name><surname>Banks</surname><given-names>G</given-names></name><name><surname>Bains</surname><given-names>RS</given-names></name><name><surname>Nolan</surname><given-names>PM</given-names></name><etal></etal></person-group>. <article-title>Disruption of the homeodomain transcription factor orthopedia homeobox (Otp) is associated with obesity and anxiety</article-title>. <source/>Mol Metab. (<year>2017</year>) <volume>6</volume>:<fpage>1419</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmet.2017.08.006</pub-id><pub-id pub-id-type="pmid">29107289</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camerino</surname><given-names>C</given-names></name></person-group>. <article-title>Low sympathetic tone and obese phenotype in oxytocin-deficient mice</article-title>. <source/>Obesity. (<year>2009</year>) <volume>17</volume>:<fpage>980</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2009.12</pub-id><pub-id pub-id-type="pmid">19247273</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasif</surname><given-names>S</given-names></name><name><surname>de Souza</surname><given-names>FS</given-names></name><name><surname>Gonzalez</surname><given-names>LE</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Orquera</surname><given-names>DP</given-names></name><name><surname>Low</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Islet 1 specifies the identity of hypothalamic melanocortin neurons and is critical for normal food intake and adiposity in adulthood</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2015</year>) <volume>112</volume>:<fpage>E1861</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1500672112</pub-id><pub-id pub-id-type="pmid">25825735</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Bonnefond</surname><given-names>A</given-names></name><name><surname>Tamanini</surname><given-names>F</given-names></name><name><surname>Mirza</surname><given-names>MU</given-names></name><name><surname>Manzoor</surname><given-names>J</given-names></name><name><surname>Janjua</surname><given-names>QM</given-names></name><etal></etal></person-group>. <article-title>Loss-of-function mutations in ADCY3 cause monogenic severe obesity</article-title>. <source/>Nat Genet. (<year>2018</year>) <volume>50</volume>:<fpage>175</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-017-0023-6</pub-id><pub-id pub-id-type="pmid">29311637</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvignes</surname><given-names>JP</given-names></name><name><surname>Bartoli</surname><given-names>M</given-names></name><name><surname>Delague</surname><given-names>V</given-names></name><name><surname>Krahn</surname><given-names>M</given-names></name><name><surname>Miltgen</surname><given-names>M</given-names></name><name><surname>Beroud</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>VarAFT: a variant annotation and filtration system for human next generation sequencing data</article-title>. <source/>Nucleic Acids Res. (<year>2018</year>) <volume>46</volume>:<fpage>W545</fpage>-<lpage>w53</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky471</pub-id><pub-id pub-id-type="pmid">29860484</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norio</surname><given-names>R</given-names></name></person-group>. <article-title>Finnish disease heritage I: characteristics, causes, background</article-title>. <source/>Hum Genet. (<year>2003</year>) <volume>112</volume>:<fpage>441</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-002-0875-3</pub-id><pub-id pub-id-type="pmid">12627295</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>YX</given-names></name><name><surname>Segaloff</surname><given-names>DL</given-names></name></person-group>. <article-title>Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects</article-title>. <source/>J Clin Endocrinol Metab. (<year>2005</year>) <volume>90</volume>:<fpage>5632</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-0519</pub-id><pub-id pub-id-type="pmid">16030156</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>T</given-names></name></person-group>. <article-title>Adenylyl cyclase 3 haploinsufficiency confers susceptibility to diet-induced obesity and insulin resistance in mice</article-title>. <source/>Sci Rep. (<year>2016</year>) <volume>6</volume>:<fpage>34179</fpage>. <pub-id pub-id-type="doi">10.1038/srep34179</pub-id><pub-id pub-id-type="pmid">27678003</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Hepatic adenylate cyclase 3 is upregulated by liraglutide and subsequently plays a protective role in insulin resistance and obesity</article-title>. <source/>Nutr Diabetes. (<year>2016</year>) <volume>6</volume>:<fpage>e191</fpage>. <pub-id pub-id-type="doi">10.1038/nutd.2015.37</pub-id><pub-id pub-id-type="pmid">26807509</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al</surname><given-names>Tuwaijri A</given-names></name><name><surname>Alfadhel</surname><given-names>M</given-names></name></person-group>. <article-title>MYT1L mutation in a patient causes intellectual disability and early onset of obesity: a case report and review of the literature</article-title>. <source/>J Pediatr Endocrinol Metab. (<year>2019</year>) <volume>32</volume>:<fpage>409</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2018-0505</pub-id><pub-id pub-id-type="pmid">30796847</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Bolado</surname><given-names>G</given-names></name></person-group>. <article-title>Development of neuroendocrine neurons in the mammalian hypothalamus</article-title>. <source/>Cell Tissue Res. (<year>2019</year>) <volume>375</volume>:<fpage>23</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-018-2859-1</pub-id><pub-id pub-id-type="pmid">29869716</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Basdevant</surname><given-names>A</given-names></name><name><surname>Chastang</surname><given-names>N</given-names></name><name><surname>Pelloux</surname><given-names>V</given-names></name><name><surname>Lahlou</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: indication for linkage with islet 1 locus on chromosome 5q</article-title>. <source/>Diabetes. (<year>1999</year>) <volume>48</volume>:<fpage>398</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.48.2.398</pub-id><pub-id pub-id-type="pmid">10334320</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Qiao</surname><given-names>Q</given-names></name><name><surname>Di</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><etal></etal></person-group>. <article-title>ISL1 loss-of-function mutation contributes to congenital heart defects</article-title>. <source/>Heart Vessels. (<year>2019</year>) <volume>34</volume>:<fpage>658</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-018-1289-z</pub-id><pub-id pub-id-type="pmid">30390123</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Hypothalamic gastrin-releasing peptide receptor mediates an antidepressant-like effect in a mouse model of stress</article-title>. <source/>Am J Transl Res. (<year>2016</year>) <volume>8</volume>:<fpage>3097</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="pmid">27508030</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>